Home Approach Science Team News

The Future
of Aging

science to sustain motion

Swiss innovation for healthy aging, dedicated to preserving communication in the nervous system for active living and delaying associated diseases.

1.4B

Adults aged 60 or older by 2030, driving unprecedented demand for aging therapeutics

1 in 4

Older adults experience significant mobility loss or a fall each year

1 in 3

Adults over 70 live with sarcopenia, with prevalence rising sharply with age

$100B+

Annual global cost attributed to falls and sarcopenia combined

Differentiated strategy

Science to preserve
neuromuscular pathways

The neuromuscular junction (NMJ) is the vital link between motor neurons and muscle. Aging disrupts this connection, weakening neural signaling and contributing to the gradual loss of strength and mobility.

Juvion develops therapeutics from natural resources that preserve NMJ structure and function, protecting the communication between nerve and muscle that supports healthy movement throughout life.

Young vs Aging NMJ comparison

Young vs. aging NMJ

Real-time locomotion tracking

FlyGym:
Our platform technology

FlyGym is a platform for real time, continuous behavioral tracking in animal models that automatically measures and analyzes the impact of interventions on brain health during aging.

Discover FlyGym →
Scientists at Juvion Health Sciences working in the EPFL neuromuscular research lab
Lausanne, Switzerland

Our Scientific Discoveries on Aging

The Team

Founders

Trusted by leading institutions & partners